Skip to content
Screener

Whitehawk Therapeutics WHWK Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue-
EPS-$0.26Beat by $0.25
EPS estimate-$0.51

Next report

Nov 5, 2026 (in 2 months)
EPS estimate-$0.27

Financials

Q3 2025

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$19.5M-45.7%
Net income-$17.7M-41.4%
EPS (diluted)-$0.26+43.5%

Balance sheet

See full
Cash & equivalents$37.9M+24.2%
Total equity$157.2M+128%
Total assets$167.0M+94.9%

Cash flow

See full
Operating cash flow-$15.4M+2.0%
Free cash flow-$15.4M+3.1%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$89.54M—
P/S6.2×—

Profitability

See full
Gross margin89.2%+1.8pp
Operating margin-754%-1,636pp
Net margin-108.6%-38.9pp
FCF margin-667.3%-1,359pp

Returns & leverage

See full
Return on equity-13.8%-6.1pp
Current ratio16.8×+11.9×

Segments

By segment

See full
Reportable--100%

FAQ

When did Whitehawk Therapeutics report Q3 2025 earnings?
Whitehawk Therapeutics (WHWK) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Whitehawk Therapeutics's Q3 2025 revenue and EPS?
Whitehawk Therapeutics reported revenue of - and eps of $-0.26 for Q3 2025.
Did Whitehawk Therapeutics beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.51 by $0.25.
Where can I find Whitehawk Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-268134) and the 10-Q periodic report (0001193125-25-268895) directly on SEC EDGAR. The filing index links above go to sec.gov.